Lv1
40 积分 2024-07-19 加入
Abstract 6580: A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models
14小时前
已关闭
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case
19天前
已完结
O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
19天前
已完结
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
21天前
已完结
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy
23天前
已完结
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment
23天前
已关闭
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
23天前
已完结
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
26天前
已完结
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
27天前
已完结
Zevalin radioimmunotherapy offers safe and effective therapy for relapsed or refractory, B cell non-Hodgkin's lymphoma (nhl)
29天前
已完结
皖公网安备34019202002308
